Consider ovarian cancer risk when deciding on HRT CANCER: Erlotinib-bevacizumab combo beats bevacizumab alone CMA: Session tackles physician-investor concerns Debit payments most popular with retailers Ontario study reheats rosiglitazone controversy Research recommends avoiding the medication due to cardiovascular risks DIABETES: Sugar-sweetened colas linked to gestational diabetes OB/GYN: Vaginal dryness a touchy topic Patients like NPs: survey Private insurance for MD-services doable DIABETES: Trial suggests rosiglitazone concerns may be overblown First Previous 526 527 528 529 530 Next Last
